In that regard, however, it is interesting to note that the secretion of CCL5 induced by alisertib (so-called senescence-associated secretory phenotype) in other cancer models actually increased rather than decreased tumor infiltrating lymphocytes [41]. This evidence concerns the gene CCL5 and neoplasm.